These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
677 related articles for article (PubMed ID: 16453260)
1. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260 [TBL] [Abstract][Full Text] [Related]
2. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA J Infect Dis; 2005 Feb; 191(4):515-9. PubMed ID: 15655774 [TBL] [Abstract][Full Text] [Related]
3. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Poland GA Vaccine; 2007 Apr; 25(16):3090-100. PubMed ID: 17280755 [TBL] [Abstract][Full Text] [Related]
4. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine. St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026 [TBL] [Abstract][Full Text] [Related]
5. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA Hum Immunol; 2004 Dec; 65(12):1506-15. PubMed ID: 15603879 [TBL] [Abstract][Full Text] [Related]
6. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. Jokinen S; Osterlund P; Julkunen I; Davidkin I J Infect Dis; 2007 Sep; 196(6):861-7. PubMed ID: 17703416 [TBL] [Abstract][Full Text] [Related]
7. Humoral and cellular immune response after measles vaccination in Taiwan. Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066 [TBL] [Abstract][Full Text] [Related]
8. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638 [TBL] [Abstract][Full Text] [Related]
9. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
11. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Ovsyannikova IG; Jacobson RM; Vierkant RA; Shane Pankratz V; Jacobsen SJ; Poland GA Vaccine; 2004 May; 22(15-16):1914-20. PubMed ID: 15121303 [TBL] [Abstract][Full Text] [Related]
12. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children. Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235 [TBL] [Abstract][Full Text] [Related]
13. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes. Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children. Glikmann G; Petersen I; Mordhorst CH Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817 [TBL] [Abstract][Full Text] [Related]
15. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
17. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001 [TBL] [Abstract][Full Text] [Related]
18. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R; Rahman MM; Hassan Z; Hassan MS Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626 [TBL] [Abstract][Full Text] [Related]
20. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM; Saunders EF; Petric M; Gold R Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]